End-of-day quote
Korea S.E.
23:00:00 30/05/2024 BST
|
5-day change
|
1st Jan Change
|
18,210
KRW
|
-3.45%
|
|
-0.22%
|
+24.22%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
287,053
|
189,608
|
245,803
|
174,032
|
97,680
|
117,376
|
Enterprise Value (EV)
1 |
265,373
|
167,376
|
222,914
|
153,766
|
76,523
|
98,006
|
P/E ratio
|
-157
x
|
221
x
|
132
x
|
1,274
x
|
370
x
|
-50.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
36.6
x
|
29.9
x
|
28
x
|
21
x
|
12.7
x
|
15.1
x
|
EV / Revenue
|
33.8
x
|
26.4
x
|
25.4
x
|
18.5
x
|
9.97
x
|
12.6
x
|
EV / EBITDA
|
220
x
|
179
x
|
101
x
|
313
x
|
94.4
x
|
-154
x
|
EV / FCF
|
-39.7
x
|
-1,289
x
|
246
x
|
631
x
|
193
x
|
-39.4
x
|
FCF Yield
|
-2.52%
|
-0.08%
|
0.41%
|
0.16%
|
0.52%
|
-2.53%
|
Price to Book
|
6.15
x
|
3.97
x
|
4.99
x
|
3.58
x
|
2.01
x
|
2.53
x
|
Nbr of stocks (in thousands)
|
8,075
|
8,086
|
8,086
|
8,038
|
8,007
|
8,007
|
Reference price
2 |
35,550
|
23,450
|
30,400
|
21,650
|
12,200
|
14,660
|
Announcement Date
|
19/03/19
|
30/03/20
|
19/03/21
|
23/03/22
|
22/03/23
|
27/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
7,850
|
6,346
|
8,789
|
8,300
|
7,678
|
7,772
|
EBITDA
1 |
1,206
|
936.3
|
2,210
|
490.7
|
811
|
-637.6
|
EBIT
1 |
872.8
|
346
|
1,580
|
-98.01
|
229.6
|
-1,185
|
Operating Margin
|
11.12%
|
5.45%
|
17.98%
|
-1.18%
|
2.99%
|
-15.24%
|
Earnings before Tax (EBT)
1 |
-552.4
|
864.4
|
2,086
|
66.21
|
201.6
|
-2,563
|
Net income
1 |
-1,826
|
855.6
|
1,852
|
139.3
|
264.5
|
-2,323
|
Net margin
|
-23.26%
|
13.48%
|
21.07%
|
1.68%
|
3.44%
|
-29.88%
|
EPS
2 |
-226.3
|
105.9
|
229.9
|
17.00
|
33.00
|
-290.1
|
Free Cash Flow
1 |
-6,681
|
-129.8
|
905.1
|
243.7
|
396.9
|
-2,484
|
FCF margin
|
-85.11%
|
-2.05%
|
10.3%
|
2.94%
|
5.17%
|
-31.96%
|
FCF Conversion (EBITDA)
|
-
|
-
|
40.96%
|
49.66%
|
48.94%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
48.87%
|
174.98%
|
150.06%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/19
|
30/03/20
|
19/03/21
|
23/03/22
|
22/03/23
|
27/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
21,680
|
22,232
|
22,889
|
20,267
|
21,157
|
19,370
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-6,681
|
-130
|
905
|
244
|
397
|
-2,484
|
ROE (net income / shareholders' equity)
|
-4.51%
|
1.76%
|
3.77%
|
0.1%
|
0.53%
|
-4.93%
|
ROA (Net income/ Total Assets)
|
1.15%
|
0.45%
|
2%
|
-0.12%
|
0.28%
|
-1.48%
|
Assets
1 |
-159,245
|
190,213
|
92,791
|
-115,278
|
94,334
|
157,267
|
Book Value Per Share
2 |
5,781
|
5,914
|
6,093
|
6,046
|
6,070
|
5,803
|
Cash Flow per Share
2 |
156.0
|
202.0
|
201.0
|
325.0
|
101.0
|
264.0
|
Capex
1 |
917
|
60.2
|
92.5
|
16.2
|
15.5
|
36.1
|
Capex / Sales
|
11.68%
|
0.95%
|
1.05%
|
0.2%
|
0.2%
|
0.46%
|
Announcement Date
|
19/03/19
|
30/03/20
|
19/03/21
|
23/03/22
|
22/03/23
|
27/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +24.22% | 105M | | -2.29% | 89.87B | | -3.95% | 37.57B | | -13.07% | 32.75B | | +63.05% | 26.47B | | -22.14% | 14.25B | | -7.96% | 12.99B | | -9.33% | 11.93B | | -46.33% | 10.84B | | +5.77% | 9.11B |
Biopharmaceuticals
|